d33ply
d33ply - AI Investigative Podcast
AI-powered investigative journalism. Deep analysis of trending topics across technology, science, politics, and culture.
Where to listen?
Podcasts in the app Replaio Radio Coming soonPodcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts
Episodes
Cursor's 30,000-engineer claim and Nvidia's telling silence 13.02.2026 20:00
A two-year-old startup valued at $9.9 billion claims nearly every Nvidia engineer uses its AI code editor. Nvidia has said nothing to confirm it. The episode examines what unverifiable marketing claims reveal about the AI coding tool gold rush and the fragile economics of developer tooling. More episodes at d33ply.xyz
Forbes and the mogul myth: 20 interviews, 100 years, zero hard questions 12.02.2026 20:00
From Henry Ford in 1928 to Elon Musk in 2003, Forbes has offered America's wealthiest entrepreneurs a platform to craft origin myths unchallenged. An examination of how access journalism doubles as a credentialing machine — and who absorbs the cost. More episodes at d33ply.xyz
Bitso's $12B secret: most of it is remittances, not trading 11.02.2026 20:00
Bitso has processed over $12B in transactions across Latin America, but the bulk of its volume comes from cross-border remittances and currency hedging — not speculation. An examination of how a Mexico City crypto exchange became financial infrastructure for a region where 57% of adults lack bank accounts, and whether that parallel system can hold. More episodes at d33ply.xyz
OpenAI's conscience was a nonprofit. Now it's a Pentagon contractor. 11.02.2026 20:00
Between 2023 and 2025, OpenAI deleted its weapons prohibition, appointed a former NSA director to its board, and deployed ChatGPT on classified military networks. The trajectory from AI safety nonprofit to defense partner traces a $40 billion incentive structure that made each step feel inevitable. More episodes at d33ply.xyz
Artemis and the case for the Moon as Mars rehearsal 10.02.2026 20:00
NASA's Artemis program frames the Moon not as a rival destination to Mars but as a prerequisite — a proving ground three days from Earth where life-support failures remain survivable. The logic rests on physics, biology, and resource engineering that Mars-first advocates tend to underestimate. More episodes at d33ply.xyz
Manchester's ex-criminal hackers are coming for your 12-year-olds 08.02.2026 20:00
A programme run by former convicted hackers is recruiting secondary school students in Manchester, redirecting young technical talent toward cybersecurity careers before the criminal justice system intervenes. With 3.5 million unfilled cybersecurity positions projected by 2026, the initiative tests a discomforting premise: the skills that produce elite defenders and dangerous criminals are identic...
André Ricciardi is dying. A24 is betting his comedy about it will sell. 04.02.2026 20:00
A terminally ill man's cancer documentary won two Sundance 2025 awards and earned a 92% on Rotten Tomatoes. With A24 and Sandbox Films backing a theatrical release, the film tests whether dark humor can work as both art and public health message. More episodes at d33ply.xyz
The NHS bet £150M that one blood test can catch 50 cancers early 03.02.2026 20:00
A multi-cancer early detection test backed by £150 million in NHS funding is nearing its first large-scale results from 140,000 participants. The trial could reshape screening for dozens of cancers that currently go undetected until late stages — or expose the limits of liquid biopsy technology. More episodes at d33ply.xyz
Medicare now demands proof that therapy works, and a $400B industry isn't ready 01.02.2026 20:00
New 2026 Medicare reimbursement rules tie behavioral health payments to demonstrated patient outcomes for the first time. After decades of intuition-driven practice, therapists and telehealth startups face a measurement-based care mandate that could reshape how mental health treatment is delivered and funded. More episodes at d33ply.xyz
Boston Scientific's $14.5B bet on the blood clot vacuum 28.01.2026 20:00
Boston Scientific is paying ten times revenue to acquire Penumbra, a maker of mechanical thrombectomy devices used in 180,000 procedures last year. The deal signals that independent medtech companies face a scaling ceiling — and that the era of consolidation in life-saving hardware has arrived. More episodes at d33ply.xyz
Similar podcasts
Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.